Article
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.
Future oncology (London, England) - 1 Dec 2013
Krell Daniel, Mulholland Paul, Frampton Adam E, Krell Jonathan, Stebbing Justin, Bardella Chiara
Abstract excerpt
Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG). Somatic mutations in genes encoding IDH1 and IDH2 were first identified in glioma and subsequently in acute myeloid leukemia and other solid tumors. These heterozygous point mutations occur at the arginine residue of the enzyme's active site and cause both loss of normal enzyme function and gain of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.